FIZE Medical
01What it doesEvidence still neededOpen review status ↗
The source supports FIZE Medical and a flagship platform, FIZE kUO, delivering continuous real-time urine-output data to clinicians for earlier AKI detection. However, the draft narrows this to 'urine-output monitoring software'; the document calls FIZE Optima a software platform, but does not clear
02Who is involvedEvidence still neededOpen review status ↗
No investor, arranger, lender, or prior-round investor information appears in the supplied document. The draft correctly does not name any investors and states that no supplied source names Series B investors, lenders, arrangers, or roles.
03What happenedEvidence still neededOpen review status ↗
The supplied document contains no Series B financing announcement, amount, currency, valuation, closing date, or completed financing status. The draft correctly marks eventMatch false and states that no supplied source establishes a Series B amount, currency, announcement date, or financing status.
04Why it mattersIts product may help intensive-care teams detect kidney injury earlier and manage patient fluids more accurately.Interpretation · Explore ↗
Checked 2026-09-17 · Review due 2026-09-24
Read supporting source ↗By transforming urine output into…
FIZE Medical · Financing Record
Explore source-linked visual explanations for FIZE Medical. Unsupported claims are withheld while source review continues.
Record 12505 · Recorded date: 2026-09-17
Explore company records →